Abstract
Introduction
Haemogloblin A1c (HbA1c) is a glycated form of haemoglobin (Hb) that is formed when the NH2-terminal valine residue of the β chain of globin is glycated [1] . It is most often used to assess glycaemic control over the previous three months.
HbA1c and other glycated haemoglobins, constitute the HbA1 fraction of adult hemoglobin (HbA). HbA1c is the predominant hemoglobin found in HbA1 fractions [1] .
Since 2010, there has been a change in using HbA1c for more than just glycaemic control and it is now accepted for the diagnosis of diabetes [2] .
The Diabetes Control and Complications Trial (DCCT) and the United Kingdom Prospective Diabetes Study (UKPDS) were two major clinical trials that showed a clear link between metabolic control (as measured by HbA1c) and the risk of chronic diabetes complications [3, 4] . Worldwide diabetic centers recommend and use specific HbA1c targets in terms of DCCT/UKPDS HbA1c.
The American Diabetes Association (ADA) guidelines recommend HbA1c levels below 7% in all diabetic patients [5] .
The value of HbA1c depends on three main factors; the Hb present in reticulocytes when these are released from the bone marrow, the glycation rate of Hb as the erythrocytes age concentration to which Hb is exposed), and the mean age of erythrocytes in the circulation [6] [7] [8] [9] .
HbA1c is currently used to evaluate the level of metabolic control, assess the risk of developing diabetic complications, and measure the quality of diabetes care. However, there are several medical conditions (not related to glycaemia) that can lead to falsely higher or lower values. The presence of Hb variants, structural haemoglobinopathies and thalassemia syndromes affect HbA1c. Any state that decreases the age span of the red blood cells will lead to lower results than the actual value of HbA1c, no matter what assay is used to measure HbA1c [10] .
Hb variants such as haemoglobin S, haemoglobin C and haemoglobin E influence certain assay methods used to measure HbA1c. Elevated haemoglobin F, which is also associated with thalassemia syndromes also affects some assay methods [11] . Other factors that affect HbA1c assays include haemolytic anaemias, haemoglobinopathies, chronic blood loss, pregnancy, opiate consumption, vitamin C ingestion, vitamin E ingestion, chronic ingestion of salicyclates, alcoholism, uremia, hyperbilirubinemia, aberrant lipid profiles, hemolytic anaemia and also in recovery from acute blood loss [11] [12] [13] [14] [15] [16] [17] [18] [19] .
There are also ethnic and racial differences in HbA1c. Studies that compare HbA1c in groups with type 2 diabetes (T2DM) patients have shown higher HbA1c levels in African Americans, Hispanics, and Asian/Pacific Islanders when compared to Caucasians. Factors that might affect glycaemia such as age, gender, adiposity, fasting and post-load glucose were all taken into account. In fully adjusted models, up to 8% of the variance in HbA1c was observed [20] .
Anaemia and its effect on HbA1c has not been studied extensively. The presence of anaemia can lead to increased red blood cell turnover and lower values of HbA1c than actual values. The red blood cell turnover can be decreased too and this will increase glycation rate of the Hb N-terminal valine and give higher than expected values of HbA1c [21] .
Iron deficiency anaemia (IDA) is one of the most common types of anaemia found worldwide [22] . The WHO (World Health Organization) estimates that 2.1 billion people globally have iron deficiency anaemia which is approximately 30% of the world population at the time [22] [23] [24] . The prevalence of iron deficiency is higher in low and high income countries. Adolescents, children and women are the most susceptible. In these countries, diabetes is also a rapidly increasing issue [25] .
Studies conducted in the 1980 -1990s
One of the earliest studies investigating the effects of IDA on HbA1c measurements was performed by Horton and Husiman and showed that the mean concentration of HbA1c was 4.9% in IDA patients compared to 5.3% in healthy individuals [12] . Also, Brooks et al. discovered that non-diabetic individuals with IDA had increased mean concentrations of Hb after 6 weeks of iron therapy. The mechanism that led to increased glycosylated HbA1 levels in IDA was not clear, but it was postulated that the quarternary structure of the haemoglobin molecule was altered in IDA. This allowed the β globin to be more readily glycosylated in the face of low iron levels. It was also speculated that if haemoglobin glycosylation is linked to microvascular complications, then diabetics with IDA could be at greater risk [26] .
However, Sluiter et al [27] postulated that formation of glycated haemoglobin is irreversible and the HbA1c concentration in a red blood cell increases with the cell age. In individuals with normal blood glucose and normal red blood cell life span, the HbA1c levels should be normal. In those individuals where the red blood cells have a shorter life span, a phenomenon that often occurs after iron treatment, HbA1c levels will decrease. If the IDA is chronic, red blood cell production will decrease leading to anaemia and a longer life span of red blood cells in the circulation. This would lead to an increased HbA1c [27] .
Mitchell et al.
[28] used the mean cell haemoglobin to calculate the absolute amount of HbA1 in each red cell before iron therapy and 6 weeks later. The amounts of HbA1c were 1.9 pg and, respectively 1.95 pg, which pointed to no significant difference of iron therapy on HbA1c. Thus it was considered unlikely that red blood cell age was a significant factor in IDA treatment [28] .
In a patient who had IDA and T2DM, Davis et al reported that the glycated Hb concentration decreased from 15.4% to 11%, independent of glycaemic control which was assessed by blood glucose concentration [29] .
Using the affinity chromatography to measure glycosylated haemoglobin in nondiabetic IDA patients, it was found that the mean glycosylated Hb was not significantly different from normal. The values did not alter significantly after iron treatment. It was assumed that the HbA1c value differences noted in previous studies could have appeared because of the post-translational modifications of haemoglobin rather than glycosylation in IDA [28] . The modified haemoglobin would co-elute with HbA1 and affect readings in cation exchange chromatography assay methods. However, this modification however, would not affect affinity gel assays because this technique depends on the binding between the gel and glucose residues on the globin chains alone [30] .
Using colorimetric assays, ion exchange chromatography, and affinity chromatography to measure HbA1c in non-diabetic IDA patients and controls showed no significant differences between any of the methods [31] .
Other studies showed similar results but treatment with iron and vitamin B12 decreased HbA1c significantly and altered red blood cell indices. It was postulated that in IDA, the red blood cell survival rate is normal, but survival rate decreased in vitamin B12 deficiency. This affects mature and immature red blood cells. The decrease in HbA1c levels after treatment could be due to an increase in bone marrow production of red blood cells and production of new immature red blood cells. It was concluded that in patients with IDA and vitamin B12 deficiency, glycosylated haemoglobin can illustrate the changes in the red blood cell population observed when mostly immature ones are being made [32] .
However, another study showed an inverse relationship between hemoglobin levels and HbA1c in paediatric patients with and without T1DM, with one third of them having IDA. Higher HbA1c concentrations were found in diabetic patients with IDA, independent of glycaemic control. Iron supplementation decreased HbA1 in both non diabetic and diabetic groups. This could be because of young red blood cells in the blood appear after iron therapy and lead to a "dilution effect" and lowering of HbA1c. The group stated there was no correlation between HbA1c and any other parameter than Hb. Structural or affinity changes in Hb, rather than iron concentration, reflect in changes of HbA1c [33] .
Studies conducted in the 2000's and beyond
The effect of IDA on Hb subtype levels has also been studied using complete blood counts. This was done in a study using IDA individuals before and after iron therapy. Iron treatment improved RBC, Hb, Hct (haematocrit), MCV (mean corpuscular volume) and MCH (mean corpuscular volume) values but HbA1c levels decreased as much as 17%. Iron replacement used in IDA diabetics could increase the reliability of HbA1c measurements. It was postulated that in normal individuals, there is a balance between HbA and serum glucose and if the glucose remained constant, a decrease in Hb concentration could cause an increase in the glycated fraction [34] .
A study that compared non diabetics with IDA to control groups found a higher mean HbA1c in IDA individuals. HbA1c significantly decreased after a 3 month course of iron therapy [35] .
Glycosylated haemoglobin has also been studied for its potential use as an index to distinguish between IDA and thalassemia minor. In a study on non-diabetic individuals, HbA1c levels were measured in β thalassemia, IDA and healthy controls. Median glycosylated hemoglobin was lower in β-thalassemia minor than IDA patients but there was no difference between IDA and control groups. In addition, in the IDA groups there was no significant correlation between HbA1c and other haemotological paramenters. The normal HbA1c concentrations in IDA could be due to normal red blood cell survival rate and normal levels of glycosylated haemoglobin in mature red blood cells [36] .
Menopause has also been studied in respect with its link to IDA and HbA1c. Koga et al. [37] evaluated red blood cell indices and glycated haemoglobin in pre-menopausal women and showed that RBC count is positively associated with HbA1c, but the case is the opposite for Hb, MCH and MCV. In the post-menopausal group, none of the indices could be linked to HbA1c. The MCH index had the highest correlation coefficient for association with HbA1c in premenopausal women because a decrease of 1 pg in MCH corresponded to an increase of approximately 0.03% in HbA1c [37] . In IDA, MCV and MCH modifications are observed before total Hb and RBC count are affected [38] . In premenopausal women, menstrual blood loss can cause IDA. It was concluded that the relatively iron deficient state of premenopausal women with lower MCH would be responsible for the higher observed HbA1c levels. In IDA, a decrease in Hb concentration could lead to an increase in the glycation fraction [34, 35] . The HbA1c catabolism could be reduced in premenopausal women with lower MCH because if the red blood cell life span is increased then the HbA1c levels also increase. However, the study was not able to conclude this because information on red blood cell life span was contradictory [39] [40] [41] .
Later Koga et al. [42] conducted a study to relate iron metabolism indices with HbA1c in premenopausal women. The women had normal glucose tolerance and were grouped into those with IDA or iron deficient state (IDS) and the normal iron state (NIS). HbA1c levels were shown to be inversely associated with serum iron, serum transferrin saturation and serum ferritin. HbA1c levels were significantly higher in IDA and IDS than in the NIS group. It was concluded that iron deficiency increases HbA1c in premenopausal women regardless if the anaemia is yet present or not [42] .
Pregnant women have also been studied to find a correlation between HbA1c levels and glycaemia in late pregnancy. In this stage, most women already have IDA. Using erythrocyte indices and iron metabolism indices, two studies by Hashimoto et al. [43] included non-diabetic pregnant women and later diabetic pregnant women not supplemented with iron. In both studies, the HbA1c levels were significantly increased in late pregnancy. HbA1c levels showed a negative correlation with MCH, serum transferrin saturation and serum transferrin. It was concluded that the late pregnancy increase in HbA1c levels was because of the IDA presence at this stage [43] .
A study involving non-diabetic pregnant women with and without IDA and an age matched control group, analysed the influence of iron metabolism indices on HbA1c and found a significant correlation between HbA1c and red blood cell and iron metabolic indices. Amongst the women who had confirmed IDA, HbA1c, OGTT (oral glucose tolerance test), red blood cell and iron metabolic indices were measured before and after iron treatment. The results indicated that HbA1c levels were higher in women with IDA, and after iron supplementation, the HbA1c levels decreased. A significant correlation between HbA1c and red blood cell and iron metabolic indices was observed [44] .
In the National Health and Nutrition Examination Survey (NHANES), observations of iron deficiency and HbA1c levels amongst non-diabetic adults showed that IDA increased the HbA1c level slightly and this occurred at the lower end of HbA1c levels i.e. between <5.5% and 5.5-6.0%. It could not be shown whether this was also the case in the higher end of the HbA1c spectrum [45] .
Using cross-sectional data on HbA1c levels from the NHANES study, observations on IDA and non-IDA states showed there was a significant positive correlation between Hb concentrations and HbA1c among participants with and without iron deficiency [46] . There was a negative correlation between erythrocyte size and Hb with HbA1c which supported the theory that iron deficiency increases Hb glycation [47] .
Another study that included T2DM patients with chronic kidney disease receiving treatment with intravenous iron and/or erythrocyte stimulating agents (ESA) found that mean HbA1c values fell in both groups. This showed that there was a statistically important decrease in HbA1c after treatment, regardless of glycaemic control [48] .
A study by Ford et al. [46] analyzing the influence of iron-deficiency anemia and noniron-deficiency anemia on HbA1c levels among adults in the US revealed a significant positive correlation between Hb concentrations and HbA1c. After adjusting for age, gender, and race, the mean HbA1c was 5.28% in participants with Hb < 100 g/L and 5.72% in participants with Hb > 170 g/L. The adjusted mean concentrations of HbA1c were 5.56% and 5.46% among participants with and without iron deficiency, respectively (P = 0.095). They suggested, in contrast to previous studies, that IDA had little population effect on HbA1c. The difference in concentrations of HbA1c between extremes of concentrations of Hb was 0.2%. It was concluded that people with anemia who are close to the diagnostic threshold should be retested or undergo another diagnostic method [46] .
Another more recent study showed that when comparing HbA1c levels in patients with IDA, it was found that the mean baseline level of HbA1c in anaemic patients is lower and increases after treatment. The subsequent increase in HbA1c after iron supplementing was in contrast to the studies conducted previously. This was explained by the fact that their study group belonged to a lower socio-economic level where the cause of IDA was nutritional deficiency, rather than bleeding and malabsorption, and this could have affected the results [49] .
Finally an Indian study that analyzed the effect of glycaemic and non-glycaemic parameters on HbA1c concentrations showed that if HbA1c is used to diagnose prediabetes and diabetes in iron deficient populations, this leads to a false high prevalence [50] . Additionally other haemotological parameters that predict higher HbA1c are anaemia and red blood cell indices of IDA such as microcytosis, low MCH, low MCHC (mean corpuscular haemoglobin concentration) or high RDW (red blood cell distribution width) and low ferritin concentrations [50] .
Conclusion
Worldwide, iron deficiency is the most common nutritional deficiency and this is especially true for the low and middle income countries. In these regions, diabetes is also a rapidly increasing phenomenon. HbA1c is a popular tool for the screening and diagnosing of diabetes. Other tests such as the OGTT are time consuming and repeated laboratory tests can become expensive for poorer populations. Nonglycaemic factors that affect assays such as conditions that affect red blood cell turnover affect HbA1c readings. Most studies indicate that, although other forms of anaemia lower HbA1c, iron deficiency anaemia appears to have an enhancing effect on HbA1c.
The mechanism of how IDA affects HbA1c remains elusive which indicates the need for further research to validate existing theories. Until large scale studies are conducted and the mechanism of increased HbA glycation in IDA states is not understood, we conclude that the reliability of HbA1c in IDA is questionable for diagnosing diabetes. People with anaemia who are close to the diagnostic threshold may need to be retested or to be diagnosed with an alternative method. HbA1c values that do not correlate with the clinical scenario or in diabetics with IDA should be approached with caution.
